134 related articles for article (PubMed ID: 8640842)
1. Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII.
Weiner LM; Alpaugh RK; Amoroso AR; Adams GP; Ring DB; Barth MW
Cancer Immunol Immunother; 1996 Mar; 42(3):141-50. PubMed ID: 8640842
[TBL] [Abstract][Full Text] [Related]
2. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
Weiner LM; Clark JI; Ring DB; Alpaugh RK
J Hematother; 1995 Oct; 4(5):453-6. PubMed ID: 8581384
[TBL] [Abstract][Full Text] [Related]
3. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
[TBL] [Abstract][Full Text] [Related]
4. In vitro cytotoxic targeting by human mononuclear cells and bispecific antibody 2B1, recognizing c-erbB-2 protooncogene product and Fc gamma receptor III.
Hsieh-Ma ST; Eaton AM; Shi T; Ring DB
Cancer Res; 1992 Dec; 52(24):6832-9. PubMed ID: 1360872
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.
Weiner LM; Clark JI; Davey M; Li WS; Garcia de Palazzo I; Ring DB; Alpaugh RK
Cancer Res; 1995 Oct; 55(20):4586-93. PubMed ID: 7553634
[TBL] [Abstract][Full Text] [Related]
6. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment.
Clark JI; Alpaugh RK; von Mehren M; Schultz J; Gralow JR; Cheever MA; Ring DB; Weiner LM
Cancer Immunol Immunother; 1997 Jul; 44(5):265-72. PubMed ID: 9247561
[TBL] [Abstract][Full Text] [Related]
7. Binding and cytotoxicity characteristics of the bispecific murine monoclonal antibody 2B1.
Weiner LM; Holmes M; Richeson A; Godwin A; Adams GP; Hsieh-Ma ST; Ring DB; Alpaugh RK
J Immunol; 1993 Sep; 151(5):2877-86. PubMed ID: 8103070
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical detection of c-erbB-2 expression by neoplastic human tissue using monospecific and bispecific monoclonal antibodies.
Garcia de Palazzo I; Klein-Szanto A; Weiner LM
Int J Biol Markers; 1993; 8(4):233-9. PubMed ID: 7908024
[TBL] [Abstract][Full Text] [Related]
9. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format.
Shahied LS; Tang Y; Alpaugh RK; Somer R; Greenspon D; Weiner LM
J Biol Chem; 2004 Dec; 279(52):53907-14. PubMed ID: 15471859
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the ability of red cells sensitized with a bispecific anti-D x anti-Fc gamma RIII Fab fragment to activate human K cells and peritoneal macrophages through Fc gamma RIII.
Bakács T; Hadley AG; Kumpel BM; Segal DM; Banhidy F
Immunol Lett; 1994 Sep; 42(1-2):91-5. PubMed ID: 7829136
[TBL] [Abstract][Full Text] [Related]
11. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
[TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
McCall AM; Adams GP; Amoroso AR; Nielsen UB; Zhang L; Horak E; Simmons H; Schier R; Marks JD; Weiner LM
Mol Immunol; 1999 May; 36(7):433-45. PubMed ID: 10449096
[TBL] [Abstract][Full Text] [Related]
13. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
[TBL] [Abstract][Full Text] [Related]
14. Activation of cloned human natural killer cells via Fc gamma RIII.
Werfel T; Uciechowski P; Tetteroo PA; Kurrle R; Deicher H; Schmidt RE
J Immunol; 1989 Feb; 142(4):1102-6. PubMed ID: 2464637
[TBL] [Abstract][Full Text] [Related]
15. Evidence for cross-regulation of Fc gamma RIIIB (CD16) receptor-mediated signaling by Fc gamma RII (CD32) expressed on polymorphonuclear neutrophils.
Naziruddin B; Duffy BF; Tucker J; Mohanakumar T
J Immunol; 1992 Dec; 149(11):3702-9. PubMed ID: 1431142
[TBL] [Abstract][Full Text] [Related]
16. Bispecific monoclonal antibody regulation of Fc gamma RIII-directed tumor cytotoxicity by large granular lymphocytes.
de Palazzo IG; Kitson J; Gercel-Taylor C; Adams S; Weiner LM
Cell Immunol; 1992 Jul; 142(2):338-47. PubMed ID: 1535829
[TBL] [Abstract][Full Text] [Related]
17. Interferon-gamma enhances monoclonal antibody 17-1A-dependent neutrophil cytotoxicity toward colorectal carcinoma cell line SW11-16.
Reali E; Guiliani AL; Spisani S; Moretti S; Gavioli R; Masucci G; Gambari R; Traniello S
Clin Immunol Immunopathol; 1994 Apr; 71(1):105-12. PubMed ID: 8137553
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies to human neutrophil Fc gamma RIII (CD16) identify polypeptide epitopes.
Fleit HB
Clin Immunol Immunopathol; 1991 May; 59(2):222-35. PubMed ID: 1706970
[TBL] [Abstract][Full Text] [Related]
19. Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor.
Repp R; Valerius T; Sendler A; Gramatzki M; Iro H; Kalden JR; Platzer E
Blood; 1991 Aug; 78(4):885-9. PubMed ID: 1714327
[TBL] [Abstract][Full Text] [Related]
20. Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy.
Valerius T; Repp R; de Wit TP; Berthold S; Platzer E; Kalden JR; Gramatzki M; van de Winkel JG
Blood; 1993 Aug; 82(3):931-9. PubMed ID: 7687898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
